Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Sickle Cell Disease: early-phase trial registry
95 of 214 indexed Sickle Cell Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #43 of 28,707 conditions by registered trial count.
214 US clinical trials · 95 currently recruiting · #43 of 28,707 conditions by registered trial count
Sickle Cell Disease: 214 US clinical trials tracked, 95 recruiting.
Sickle Cell Disease is the subject of 214 registered US clinical trials on ClinicalTrials.gov, 95 of them currently open to new participants. 14 are in Phase 3-4 (later-stage) and 87 in Phase 1-2 (earlier-stage). The most active sponsor is St. Jude Children's Research Hospital, running 17 of these trials.
Enrollment posture brief
Registry condition sickle-cell-disease
OPEN 95 | RECR 44% | LATE 14 | EARLY 87 | RANK #43 | SPON 17
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Sickle Cell Disease lists 95 open slots (44% of 214 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Sickle Cell Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Sickle Cell Disease is recruiting above its size-band peers.
95 of 214 indexed trials (44.4%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Sickle Cell Disease trials is spread across many organizations.
St. Jude Children's Research Hospital accounts for 17 of 214 trials (7.9%). 101 distinct sponsors appear on at least one study for this condition label.
-
Most Sickle Cell Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 214 trials that report a genuine target (sentinel values excluded). 150 of those (70.1%) plan for fewer than 100 participants.
-
Sickle Cell Disease research is mostly interventional.
160 interventional and 54 observational studies make up this index (74.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
214 total, page 1 of 5
Study of the Role of Genetic Modifiers in Hemoglobinopathies
Cyprus Institute of Neurology and Genetics
NCT05799118
Sickle Cell Clinical Research and Intervention Program
St. Jude Children's Research Hospital
NCT02098863
Investigation of the Genetics of Hematologic Diseases
St. Jude Children's Research Hospital
NCT02720679
Cooperative Assessment of Late Effects for SCD Curative Therapies
Vanderbilt University Medical Center
NCT05153967
Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
RTI International
NCT06385886
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Novo Nordisk A/S
NCT06609226
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
University of Pittsburgh
NCT06374238
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Novo Nordisk A/S
NCT06612268
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
Pfizer
NCT05431088
Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders
St. Jude Children's Research Hospital
NCT04416178
Cerebral Oxygen Metabolism in Children
Washington University School of Medicine
NCT04157179
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Novartis Pharmaceuticals
NCT06439082
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03937817
Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
Ohio State University
NCT06919224
SMYLS Multi-site Trial
Medical University of South Carolina
NCT06035939
Blood Sampling for Research Related to Sickle Cell Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00542230
Exercise in Child Health
University of California, Irvine
NCT05359991
Acupressure in Patients With Sickle Cell Disease
Indiana University
NCT06511453
Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation
Children's Hospital Medical Center, Cincinnati
NCT04093986
Tocilizumab for Acute Chest Syndrome
University of Chicago
NCT05640271
The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease
Sanofi
NCT06975865
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
University of Florida
NCT04484272
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
NCT06546670
Integrative Training Program for Pediatric Sickle Cell Pain
Emory University
NCT06691867
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Novartis Pharmaceuticals
NCT04657822
Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
Children's Hospital Medical Center, Cincinnati
NCT07356050
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
Mohsen Saidinejad
NCT07369024
Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0
Indiana University
NCT06725550
Cognitive Remediation Intervention to Prepare for Transition of Care
University of Alabama at Birmingham
NCT05336201
Metabolic and Hemodynamic Reserve in Pediatric SCA
Washington University School of Medicine
NCT04406818
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
Robert Nickel
NCT03587272
Early Screening and Treatment of Heart Complication in Sickle Cell Disease
Inova Health Care Services
NCT07023666
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
National Heart, Lung, and Blood Institute (NHLBI)
NCT06313398
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
Sanofi
NCT07247188
Sickle Cell Disease Biofluid Chip Technology (SCD BioChip)
University Hospitals Cleveland Medical Center
NCT02824471
Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease
Suvankar Majumdar
NCT06635902
MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease
University of California, Irvine
NCT06853158
Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease
National Institutes of Health Clinical Center (CC)
NCT05170412
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
St. Jude Children's Research Hospital
NCT03353584
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
St. Jude Children's Research Hospital
NCT07226219
Predictors of Pain in Sickle Cell Disease
Duke University
NCT06139510
Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX)
St. Jude Children's Research Hospital
NCT05810181
Empowering Adolescents and Young Adults With Sickle Cell Disease as Partners in Treatment Decision Making (EMPOWER-AYA)
Nemours Children's Clinic
NCT05383911
Peripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease
St. Jude Children's Research Hospital
NCT06477289
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
CSL Behring
NCT07224360
Allo HSCT for High Risk Hemoglobinopathies
Masonic Cancer Center, University of Minnesota
NCT06872333
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
Washington University School of Medicine
NCT06689800
Applying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness
Nationwide Children's Hospital
NCT06264700
Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
Icahn School of Medicine at Mount Sinai
NCT05519111
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
Agios Pharmaceuticals
NCT06924970
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 39 |
| Phase 2 | 48 |
| Phase 3 | 11 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Sickle Cell Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Sickle Cell Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Sickle Cell Disease page
214 registered trials, 95 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 95 Sickle Cell Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- St. Jude Children's Research Hospital sponsors the most Sickle Cell Disease trials on record, review their full trial history before evaluating a specific study. See St. Jude Children's Research Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sickle Cell Disease condition card totals 214 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.